Stockwinners Market Radar for April 13, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:27 EDT Cathie Wood's ARK Investment bought 1.55M shares of Ginkgo Bioworks today

19:09 EDT Berkeley Lights names Lucas Vitale chief HR officer - Berkeley Lights announced the appointment of Lucas Vitale to the newly created role of Chief Human Resources Officer, effective immediately. Vitale will lead Berkeley Lights' Human Resources function. He will report directly to the company's Chief Executive Officer, Dr. Siddhartha Kadia. As Berkeley Lights' newly appointed CEO, Dr. Kadia is focused on the further development of its human capital and talent function to support the Company's growth opportunities. "With two decades of experience in all facets of human resources in the life sciences industry, Lucas is a skilled leader with a talent for building and scaling organizations and high-performance leadership teams," said Dr. Kadia. "In his new role, Lucas will support the development of our teams, processes and operations by drawing on his passion for people and experience in scaling organizations. As Berkeley Lights continues advancing its strategic priorities, we will also benefit from Lucas' experience in thoughtfully guiding the cultural evolution necessary to support transformative growth."

17:56 EDT Regulator allows WhatsApp to extend payment services to 100M users in India - In an earlier release on Wednesday, the regulatory body that developed the UPI instrument in India, the National Payments Corporation of India, or NPCI has approved an additional 60M users on UPI for WhatsApp (FB, META). With this approval, WhatsApp will be able to expand the service to its 100M users. The Fly noted that companies that have similar services in India include rivals Google Pay (GOOG, GOOGL) and Walmart (WMT)-backed PhonePe. Reference Link

17:35 EDT Wells Fargo commits $210M to help with 'systemic inequities' in housing market - "Systemic inequities in the United States have prevented too many minority families from achieving their homeownership and wealth building goals for too long. As the largest bank home mortgage originator, and largest bank originator of home loans to minorities over the last decade, Wells Fargo believes it has a responsibility to develop solutions that help close the gap. As a next step in meeting that responsibility, Wells Fargo announced a new initiative to help advance racial equity in homeownership across the country. The company will develop a Special Purpose Credit Program, SPCP, to help minority homeowners, whose mortgages are currently serviced by Wells Fargo, refinance those mortgages. Initially, through the program, Wells Fargo will identify eligible Black homeowners who could benefit from a refinance product. Wells Fargo will commit $150M to lower mortgage rates and reduce the refinancing costs to help these homeowners further benefit from refinancing. This program goes beyond the usual lending programs and puts the company's own money to work refinancing minority families' homes," said the lender in a statement. Wells Fargo said it will also "assess its progress and will publicly disclose it annually. Commit, through the Wells Fargo Foundation, $60M "Wealth Opportunities Restored through Homeownership," WORTH, grants projected to support 40,000 homeowners of color in eight markets that have significant homeownership gaps between white and minority families. WORTH grants will run through 2025 and will fund public-private partnerships that develop and implement plans to address the root causes of those homeownership gaps."

17:30 EDT Genmab and AbbVie report Phase 1/2 results of epcoritamab in LBCL - Genmab (GMAB) and AbbVie (ABBV) announced topline results from the first cohort of the EPCORE NHL-1 phase 1/2, clinical trial evaluating epcoritamab - DuoBody CD3xCD20 -, an investigational subcutaneous bispecific antibody. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma - LBCL - who received at least two prior lines of systemic therapy. Based on the topline results, the companies will engage global regulatory authorities to determine next steps. Topline results from this cohort demonstrated an overall response rate of 63.1%, exceeding the protocol prespecified threshold for efficacy. The most common treatment-emergent adverse event was cytokine release syndrome with 49.7%. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' broad oncology collaboration. LBCL is a fast-growing type of non-Hodgkin's lymphoma that affects B-cell lymphocytes.

17:27 EDT Rocket Companies CEO buys $598K in common stock - In a regulatory filing, Rocket Companies disclosed that its CEO Jay Farner bought 61.5K shares of common stock on April 11th in a total transaction size of $598K.

17:13 EDT Box CFO Smith sells $429K in company shares - Box CFO Dylan Smith disclosed in a filing that he had sold 15,000 shares of company stock at $28.62 per share on April 11, for a total transaction amount of $429,360.

17:02 EDT Cushman & Wakefield acquires Sheffield Property, Sheffield Asset Management - Cushman & Wakefield has acquired Sheffield Property Pty Ltd. and Sheffield Asset Management Pty Ltd., an office leasing and property management agency based in Perth, Western Australia. The acquisition further strengthens Cushman & Wakefield's well established and full service commercial real estate platform across Australia and the Asia Pacific region.

16:54 EDT Orchid Island Capital estimates book value per share of $3.34 as of March 31 - Orchid Island Capital announced that the Board of Directors declared a monthly cash dividend for the month of April 2022. The dividend of 4.5c per share will be paid May 27, 2022 to holders of record of the company's common stock on April 29, 2022, with an ex-dividend date of April 28, 2022. The company plans on announcing its next common stock dividend on May 11, 2022. The Company's estimated book value per share as of March 31, 2022 was $3.34. The Company computes book value per share by dividing total stockholders' equity by the total number of outstanding shares of common stock. At March 31, 2022, the Company's preliminary estimated total stockholders' equity was approximately $592.4 million with 177,117,186 shares of common stock outstanding. These figures and the resulting estimated book value per share are preliminary, subject to change, and subject to review by the Company's independent registered public accounting firm. The Company estimates it generated a net loss per share of $0.84, which includes $1.04 per share of net realized and unrealized losses on RMBS and derivative instruments for the quarter ended March 31, 2022. These amounts compare to total dividends declared during the quarter of $0.155 per share. Net loss per common share calculated under generally accepted accounting principles can, and does, differ from our REIT taxable income. The Company views REIT taxable income as a better indication of income to be paid in the form of a dividend rather than net loss. Many components of REIT taxable income can only be estimated at this time and our monthly dividends declared are based on both estimates of REIT taxable income to be earned over the course of the current quarter and calendar year and a longer-term estimate of the REIT taxable income of the Company. These figures are preliminary, subject to change, and subject to review by the Company's independent registered public accounting firm. The Company's estimated total return on equity for the quarter ended March 31, 2022 was (19.5)%. The Company calculates total return on equity as the sum of dividends declared and paid during the quarter plus changes in book value during the quarter, divided by the Company's stockholders' equity at the beginning of the quarter. The total return was $(0.845) per share, comprised of dividends per share of $0.155 and a decrease in book value per share of $1.00 from December 31, 2021.

16:36 EDT Cambium Networks drops 12% to $17.83 after lowering Q1 revenue view - The company also announced a CFO change.

16:31 EDT Ansys to acquire OnScale, terms undisclosed - Ansys announced that it has signed a definitive agreement to acquire cloud simulation provider OnScale. Once integrated into Ansys' existing cloud portfolio, this technology acquisition will help provide a cloud-native, web-based user interface, or UI, for device-independent access to Ansys' broad array of simulation technologies. Terms of the deal were not disclosed. The acquisition is not expected to have a material impact on Ansys' consolidated financial statements in 2022.

16:30 EDT Cambium Networks trading resumes

16:17 EDT Earthstone Energy EVP Oviedo sells 50,000 class A shares - In a regulatory filing, Earthstone Energy executive VP Tony Oviedo disclosed the sale of 50,000 class A common shares of the company on April 12 at a price of $13.71 per share.

16:16 EDT Sonida Senior Living names Kevin Detz as new CFO - Sonida Senior Living "announced the appointment of Kevin Detz, CPA, as CFO, effective May 1, 2022. Detz joins Sonida from Aimbridge Hospitality, the leading third-party global hotel management company, where he most recently served as Executive Vice President and Operational CFO."

16:15 EDT Airgain secures multi-million dollar contract with major utility - Airgain announced that a major US-based water utility company has selected AirgainConnect AC-HPUE to improve the connectivity of its fleet. With up to 10x the power and up to 4x the coverage area of a traditional router-mounted antenna, the utility plans to equip its 3,000 plus vehicle fleet with the roof-mounted antenna-modem to enable optimum connectivity, even in the most remote and difficult environments. The multimillion dollar contract for the AirgainConnect devices will be deployed through the end of the year. Morad Sbahi, Senior Vice President, Global Product & Marketing at Airgain added, "When we launched the AirgainConnect platform almost a year and half ago, we were looking to solve the connectivity issues that had long plagued public safety and critical infrastructure. By equipping the fleet of a major utility with the AirgainConnect AC-HPUE, we can help its service technicians, inspectors, engineers and field operators to stay connected in order to deliver water where it is needed most."

16:12 EDT Accolade announces partnership with Priority Health - Priority Health "announced a strategic partnership with Accolade to bring a differentiated health care experience to Michigan employers in the commercial group market and their members. Priority Health and Accolade share a mission to help employees maximize their health plan benefits by creating a member experience uniquely tailored to each person's needs and preferences. Through this partnership, Priority Health and Accolade will bring together virtual care services and personalized navigation capabilities to enable innovative plan designs and a comprehensive support model for Priority Health members."

16:09 EDT Simply Good Foods announces $50M addition to share repurchase program - Simply Good Foods announced that its board of directors has approved the addition of $50M to its existing stock repurchase program, which was first adopted in November 2018. As of April 13, an aggregate of approximately $76.2M is available under company's stock repurchase authorization. As of the second fiscal quarter ended February 26, the company had cash and cash equivalents of $51.5M and anticipates its FY22 cash flow from operations to be about the same as last year.

16:07 EDT Synchronoss appoints Stanley Lowe as chief information security officer - Synchronoss (SNCR) announced the addition of Stanley Lowe to the company's executive management team as chief information security officer, or CISO. Lowe will report directly to Patrick Doran, chief technology officer. Lowe brings to Synchronoss more than 20 years of experience in information security and cybersecurity. Most recently, he was Global Chief Information Security Officer at Zscaler (ZS).

16:06 EDT Amneal says FDA approves BLA for Alymsys, a biosimilar referencing Avastin - Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the company's Biologics License Application for bevacizumab-maly, a biosimilar referencing Avastin. The product will be marketed under the proprietary name ALYMSYS and represents the third bevacizumab biosimilar approved in the U.S. "ALYMSYS was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals. Bevacizumab-maly is a vascular endothelial growth factor inhibitor used in oncology. This marks the second of three biosimilars approvals Amneal expects to receive this year in oncology, the second-largest biosimilar category in the U.S. Earlier this year, Amneal received approval of RELEUKO, a filgrastim biosimilar referencing Neupogen, and the company's pegfilgrastim biosimilar referencing Neulasta is currently under review by the FDA," the company said. "With the U.S. approval of our second biosimilar, ALYMSYS, we are continuing our momentum and establishing our presence in the $28 billion U.S. biosimilars market. By combining partner assets with our own key capabilities, we are on a clear path to becoming a meaningful player in this high growth category. Biosimilars represent the next wave of affordable medicines in the U.S. and are closely aligned with our strategy to provide high quality, affordable medicines to as many patients as possible," said Chirag and Chintu Patel, Co-Chief Executive Officers.

16:05 EDT Credit Acceptance announces Andrew Rostami as chief marketing, product officer - Credit Acceptance (CACC) announced that Andrew Rostami will join our senior leadership team as chief marketing and product officer on April 18. In his role, Rostami will help drive growth and innovation in the ways we interact with and support our customers, both dealers and consumers, by ensuring that our customers' needs are supported through strategy and product development. Rostami comes to Credit Acceptance from Citizens (CFG), where he was most recently president, Citizens Pay, and EVP, head of unsecured lending and cards.

16:03 EDT Cambium Networks CFO Stephen Cumming departs, Andrew Bronstein to succeed - Cambium Networks announced the departure of Stephen Cumming as CFO, effective immediately. The board has appointed Andrew Bronstein as CFO. Andrew previously served as CFO for Cheetah Digital, a SaaS software solutions company that has been a portfolio company of Vector Capital, where he has been an Operating Partner.

15:13 EDT Chimerix confirms remains in active negotiations with BARDA on Tembexa - In a regulatory filing, Chimerix announced that it is aware of unusual trading activity in the company's common stock for a period of time. "The company believes the unusual trading activity may be attributable to statements regarding smallpox antiviral development and procurement contained in the Fiscal Year 2023 Congressional Justification for the Public Health and Social Services Emergency Fund published by the Department of Health and Human Services. The company confirms that it remains in active negotiations with the Biomedical Advanced Research and Development Authority, or "BARDA," regarding a sole-source contract with the company for the development and procurement of up to 1.7 million treatment courses of TEMBEXA. The company currently expects to enter into the contract in the second quarter of 2022, and for the initial shipment of TEMBEXA in an amount consistent with prior guidance of $80M-$100M to be procured and shipped to the Strategic National Stockpile soon after contract execution. As is customary, additional procurements and shipments under the contract would be subject to BARDA's option. The company does not expect to provide updates related to negotiation of the procurement agreement prior to execution with BARDA," the company stated.

14:51 EDT Scotiabank raises Canadian dollar prime lending rate to 3.2% from 2.7% - Scotiabank announced that it is increasing its Canadian dollar prime lending rate to 3.2% from 2.7%, effective April 14, 2022.

14:39 EDT FDA approves Amneal Pharmaceuticals' biosimilar to Avastin - The FDA has granted approval to Amneal Pharmaceuticals' Alymsys, a biosimilar to Avastin, for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment and metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidineoxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. Reference Link

14:16 EDT JUUL to pay Washington $22.5M over advertising practices - Washington's Attorney General Bob Ferguson has announced that JUUL must pay $22.5 million to resolve Ferguson's lawsuit against the e-cigarette company. "The lawsuit asserts that JUUL violated the law when it designed and marketed its products to appeal to underage consumers and deceived consumers about the addictiveness of its product. In addition to the payment, JUUL must stop its unlawful conduct and implement a slate of reforms, including: Stopping all its advertising that appeals to youth; Stopping most social media promotion; Accurately marketing the content and effects of the nicotine in its products; Strict practices to confirm the age of consumers who purchase JUUL products - including a robust secret shopper program and online purchase age verification. JUUL is required to conduct no fewer than 25 secret shopper checks per month at Washington-based JUUL retailers for at least two years, and perform at least one check in every Washington county per year. The company is required to send a regular report to the Attorney General's Office detailing the results of the secret shopper program every 90 days," the Attorney General's Office said. "These reforms are legally enforceable. If JUUL violates these terms, the Washington Attorney General's Office can go directly to King County Superior Court to enforce them." Under the consent decree, filed in King County Superior Court, JUUL is ordered to pay the $22.5 million total over the next 4 years. Reference Link

13:43 EDT North American rail traffic fell 1% for the week ending April 9 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending April 9.For this week, total U.S. weekly rail traffic was 508,343 carloads and intermodal units, down 1% compared with the same week last year. Total carloads for the week ending April 9 were 236,459 carloads, up 1.4% compared with the same week in 2021, while U.S. weekly intermodal volume was 271,884 containers and trailers, down 3.1% compared to 2021. Six of the 10 carload commodity groups posted an increase compared with the same week in 2021. They included coal, up 3,519 carloads, to 65,725; motor vehicles and parts, up 1,320 carloads, to 13,352; and chemicals, up 1,185 carloads, to 35,152. Commodity groups that posted decreases compared with the same week in 2021 included petroleum and petroleum products, down 2,107 carloads, to 9,319; metallic ores and metals, down 1,753 carloads, to 20,711; and miscellaneous carloads, down 551 carloads, to 9,808. North American rail volume for the week ending April 9, on 12 reporting U.S., Canadian and Mexican railroads totaled 337,598 carloads, up 0.9% compared with the same week last year, and 363,293 intermodal units, down 2.6% compared with last year. Total combined weekly rail traffic in North America was 700,891 carloads and intermodal units, down 1%. North American rail volume for the first 14 weeks of 2022 was 9,314,334 carloads and intermodal units, down 3.7% compared with 2021. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), Wabtec (WAB), FreightCar America ((RAIL). Reference Link

13:35 EDT Ford CEO announces April 26 as F-150 Lightning launch date in tweet - Ford CEO Jim Farley tweeted: "It's time. #F150Lightning 4.26.2022" with a link to a countdown clock on the company's corporate site. Reference Link

13:25 EDT Synopsys drops after report of U.S. probe, shares down 3% to $301.01

13:13 EDT Lithium Corp. says Tesla rumor false, 'no relationship' between companies - Lithium Corporation (LTUM) wishes to inform shareholders that, contrary to a press release issued by unknown parties on the 12th of April and rumors circulating on social media, "we have not received so much as an expression of interest from Tesla, Inc. and no employees have left Lithium Corporation to take up employment with Tesla." Lithium added: "We would be happy to chat with Elon if he was inclined, but presently there is no relationship between the two companies." Shares of Lithium Corp. rallied to $1.09 earlier in the day and remains up 33% to 38c in afternoon trading. Reference Link

13:02 EDT Toyota conducting noncompliance safety recall for about 460,000 U.S. vehicles - Toyota is conducting a noncompliance safety recall involving certain Toyota Venza, Mirai, RAV4 Hybrid, RAV4 Prime, Sienna HV, Highlander HV and Lexus LS500h, LX600, NX350h and NX450h+ vehicles in the U.S. Approximately 460,000 vehicles are involved in this recall. A software error can cause the Vehicle Stability Control system not to default to ON the next time the car is started under certain circumstances. This can result in a noncompliance with applicable regulations in the U.S., the company stated. For all involved vehicles, Toyota and Lexus dealers will update the software of the Skid Control ECU free of charge to customers. Owners of involved vehicles will be notified by the middle of June. Reference Link

12:25 EDT Sony, Nintendo to update subscription practices after CMA review - The U.K. Competition and Markets Authority welcomed improvements made by Sony (SONY) and Nintendo (NTDOY) to their gaming subscription practices and has now closed its investigation into the online gaming sector. The authority's sector-wide investigation looked at subscriptions for online gaming services where people automatically continue to be charged indefinitely until they take action to end their contract. The CMA was particularly concerned that people might find themselves locked into paying for services they no longer want or use. The CMA has an secured an undertaking from Sony relating to its PlayStation Plus product, a service which allows users to play online together. In particular, Sony has agreed to put in place measures to protect customers who haven't used their memberships for a long time but are still paying. Sony will contact these customers to remind them how to stop payments and, if they continue not to use their memberships, Sony will ultimately stop taking further payments. The CMA also engaged with Nintendo, which changed its business practices during the course of the investigation so that Nintendo Switch Online Service is no longer sold with automatic renewal set as the default option. This means people will not be automatically entering into renewing contracts, addressing a number of the CMA's concerns about people becoming locked in.

12:07 EDT Verizon adds calling to more countries in Latin America at no extra cost - Verizon said it has added more Latin American countries to be part of Global Choice, at no cost with select 5G Unlimited plans. With Global Choice, the international calling plan that provides a select number of long distance calling minutes, new and existing qualified customers can access up to five hours per month to call their friends and loved ones in one of 17 countries in Latin America at no additional charge, with discounted rates for additional hours. Verizon is the only carrier to include a block of monthly international calling minutes to Cuba at no additional cost, the company said. And, as always, talk and text to Mexico and Canada is included on select 5G Unlimited plans. "At Verizon we are committed to offering our Latinx customers the best value on the best network to help them stay connected to friends and family near and far," said Nina Bibby, SVP Consumer Segment Marketing at Verizon. "We are proud to expand our Global Choice international calling plan to reach more countries in Latin America, including Cuba, so customers can receive a block of minutes every month to call their chosen country at no cost."

12:00 EDT Terran Orbital falls -10.4% - Terran Orbital is down -10.4%, or -45c to $3.88.

12:00 EDT PHX Minerals rises 11.4% - PHX Minerals is up 11.4%, or 34c to $3.34.

12:00 EDT Ultrapetrol rises -0.1% - Ultrapetrol is up -0.1%, or -06c to $48.15.

11:34 EDT Foghorn Therapeutics announces preclinical data on FHD-286 - Foghorn Therapeutics announced preclinical data supporting the clinical development and mechanistic understanding of BAF inhibition through the BRG1 and BRM dual inhibitor, FHD-286, for the treatment of cancer, at the 2022 American Association for Cancer Research Annual Meeting in New Orleans, Louisiana. FHD-286 has first-in-class potential and is Foghorn's first candidate directly targeting the chromatin regulatory system to emerge from the Company's Gene Traffic Control platform. With an initial focus in oncology, Foghorn's Gene Traffic Control Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases. Abstract ND14 - Pharmacological profile and anti-tumor properties of FHD-286: A novel BAF inhibitor for the treatment of transcription factor-driven cancers: FHD-286 is the Company's selective, oral allosteric BRG1/BRM inhibitor with first-in-class potential wholly discovered and developed by Foghorn Therapeutics. Data presented demonstrate robust efficacy at well tolerated doses in xenograft and PDX models of uveal melanoma and AML, and broad therapeutic utility in AML patient derived samples. These data support the two ongoing Phase 1 trials evaluating FHD-286 in metastatic uveal melanoma as well as relapsed/refractory AML and myelodysplastic syndromes. Preclinical Data Highlights: Favorable oral bioavailability, low clearance, and favorable tolerability at doses of 1.5 mg/kg QD associated with efficacy in mouse models; Sensitivity to BAF complex inhibition by multiple cancers, including uveal melanoma and AML; Significant anti-tumor activity in AML xenograft models; Mutation agnostic responses in patient derived samples support potential for broad use across patient types with AML; Synergistic activity with different combination partners including chemotherapy agent cytarabine and targeted therapy venetoclax in primary patient samples; Pre-clinical exploration of FHD-286 in other solid and hematologic tumor types is ongoing for potential indication expansion. Abstract LB190 / 3 - Modulation of SPI1 transcriptional program contributes to the preclinical anti-tumor activity of SMARCA4/SMARCA2 ATPase inhibitors in AML: BAF inhibition with a dual inhibitor of BRG1/BRM modulates transcriptional regulator SPI1 in preclinical in vitro and in vivo models, supporting a mechanistic basis for the clinical development of FHD-286 in AML. SPI1 is a transcription factor critical to hematopoietic development and differentiation, with implications in driving oncogenesis in AML. As a master regulator of multiple lineage specific transcriptional programs, BAF inhibition offers therapeutic potential beyond SPI1 driven subtypes.Preclinical Data Highlights: Dual BAF ATPase inhibition affects SPI1 levels and downstream transcriptional program, impacting cell proliferation and cellular survival BRG1/BRM ATPase inhibition affects enhancer accessibility, reducing occupancy of SPI1 at enhancer elements in AML; Treatment with BAF inhibitor in an AML xenograft model elicited dose-dependent tumor regression at tolerated doses and pharmacodynamic modulation of SPI1 target genes, demonstrating potential therapeutic utility in AML.

11:18 EDT Winmark increases quarterly cash dividend to 70c per share - Winmark Corporation announced that its Board of Directors has approved an increase in its regular quarterly cash dividend to shareholders. The quarterly dividend of 70c per share represents an increase of 25c from its previous dividend rate. The cash dividend will be paid June 1, 2022 to shareholders of record on the close of business on May 11, 2022. Future dividends will be subject to Board approval.

11:12 EDT Opthea Ltd (ADR) trading resumes

11:03 EDT Hookipa Pharma announces preclinical data on arenaviral immunotherapies - HOOKIPA Pharma announced positive preclinical data demonstrating potent T cell responses, potential novel combination use beyond PD-1 inhibitors, and the ability to break immune tolerance to various self-antigens for targeting cancers. The results highlight the potential of HOOKIPA's novel arenaviral platform in difficult-to-treat cancers and as a backbone of potential combination therapies requiring robust T cell responses for cancer patients. The data were shared as poster presentations at the 2022 American Association for Cancer Research Annual Meeting. Preclinical data presented at AACR show that the combination of co-stimulatory 4-1BB agonists with arenaviral immunotherapy increased tumor control and resulted in a higher cure rate than arenaviral immunotherapy alone. Co-stimulatory agents, like 4-1BB agonists, are known as accelerators of cancer immunotherapy, because they help induce potent, tumor-specific T-cells that can infiltrate and kill tumors. The combination of an arenaviral immunotherapy with a 4-1BB agonistic antibody resulted in complete tumor rejection in 30 percent of mice following treatment. Importantly, improved tumor control and cure rates of up to 50 percent were also observed with a 4-1BB ligand which was integrated into the arenaviral vector. A separate preclinical analysis presented at AACR offered additional evidence of potential combination with other modalities. In this analysis, replicating arenaviral immunotherapy was sequentially combined with adoptively transferred TCR transgenic T cells, which resulted in tumor cures in all mice receiving combination therapy, with 100 percent survival at the end of the experiment. These data highlight the potential of arenaviral immunotherapies in combination with other treatment modalities beyond PD-1 inhibitors, as well as showcase the versatility of the platform as a potential backbone for various combination immunotherapies. Additional preclinical data showed antitumor activity with a single administration of replicating arenaviral immunotherapy targeting tumor self-antigens. Specifically, the arenaviral immunotherapy was able to overcome immune tolerance, induce potent T cell responses against two different tumor self-antigens and reduce tumor growth in these cancers. Notably, targeting tumor self-antigens can be a challenge because the immune system does not recognize these molecules as foreign. These preclinical data provide further support for the clinical entry of HOOKIPA's HB-300 candidate for treatment of prostate cancer. The AACR data demonstrate the ability of HOOKIPA's arenaviral immunotherapeutic technology to induce potent T-cell responses against tissue-specific self-antigens, which is the same type of tumor self-antigens targeted by HB-300. The company intends to submit an Investigational New Drug application in the third quarter of 2022. HOOKIPA's Phase 1/2 study of HB-200 for patients with Human Papillomavirus 16-positive squamous cell head and neck cancers is ongoing. Biomarker data from this study showed an unprecedented induction of tumor antigen specific CD8+ T cell responses of up to 40 percent of total CD8+ T cells. As dosing of HB-200 continued, more T cells became polyfunctional, which indicates the T cells are high quality and not exhausted. A clinical update on Phase 1 HB-200 monotherapy data is anticipated mid-year; preliminary data on HB-200 in combination with pembrolizumab as 1st-line and 2nd-line treatment for HNSCC is anticipated in the second half of 2022.

10:12 EDT Delta Air Lines 'confident' in outlook for meaningful FY profit in 2022

10:10 EDT Delta Air Lines to remain 'nimble' on capacity for 2H given macro uncertainty

10:08 EDT Portage Biotech highlights data presented on PORT-5 at AACR 2022 - Portage Biotech highlighted data being presented in collaboration with Stimunity during the American Association for Cancer Research 2022 Annual Meeting taking place April 8-13 in New Orleans, Louisiana. Preclinical data shows that PORT-5, a stimulator of interferon genes agonist, cyclic guanosine monophosphate-adenosine monophosphate packaged in a virus-like particle developed with Stimunity, can be delivered systemically and achieve potent activation of the STING pathway preferentially in dendritic cells. The data will be presented in a late-breaking research session at the AACR meeting on Wednesday, April 13. The STING pathway is a well-recognized immune-boosting pathway that primes an anti-tumor T cell response and has long been an area of interest in cancer treatment, but limitations of small molecule therapies have stymied STING-activating therapies in clinical trials, due to lack of ability to target specific dendritic cells which leads to varied effects in different cells and an inefficient T cell response. Novel approaches are needed to overcome unwanted side effects associated with activation of this pathway in humans. The promising results from Portage and Stimunity show that PORT-5 can not only target specific dendritic cells but can be customized and targeted to specific cell and tumor types across the body and could offer a differentiating option compared to current treatments.

10:07 EDT Delta Air Lines sees 'clear signs' of pent-up demand for travel, CEO says - CEO Bastian says domestic revenues are exceeding 2019 levels.

10:05 EDT Mustang Bio plans to initiate Phase 1 trial combining MB-101 with MB-108 - Mustang Bio announced its plan to initiate a Phase I clinical trial combining CAR T cells and oncolytic virus for the treatment of recurrent glioblastoma, supported by interim data from two ongoing investigator-sponsored Phase 1 clinical trials evaluating two clinical candidates, MB-108 and MB-101. Preclinical data also presented support the safety of administering these two therapies sequentially in a regimen designated as MB-109. The data are from a late-breaking poster at the American Association for Cancer Research Annual Meeting 2022. Outcomes presented by Dr. Brown from each of the clinical candidates are as follows: MB-101: City of Hope's Phase 1 clinical trial evaluated the feasibility and safety of repetitive administration of locoregionally delivered MB-101 in 65 heavily pretreated patients with recurrent or refractory malignant glioma, the majority of which were rGBM. Following maximal surgical resection / biopsy, dose escalating schedules of MB-101 were administered weekly either intratumorally, intraventricularly. Infusions appeared to be well tolerated with clinically manageable flu-like symptoms and two grade 3 events possibly related to the CAR T cells. Optimization of manufacturing and administration in the final cohort of 19 evaluable patients suggest MB-101 provides a possible survival benefit versus historical controls. Two patients with high levels of intratumoral CD3+ T cells pre-therapy achieved complete responses lasting 7.5 and 31+ months, respectively. MB-108: University of Alabama at Birmingham researchers are conducting a Phase 1 clinical trial evaluating MB-108 for rGBM that will enroll up to 24 patients. Today's poster highlights one clinical trial participant who received a single infusion of MB-108 that was well-tolerated. MRI changes at approximately 7 weeks post-treatment could not discriminate between tumor progression and pseudoprogression. Therefore, the patient underwent tumor biopsy 7 weeks post treatment that showed necrotic areas in tumor after treatment with MB-108. Immune infiltrates, both treated and untreated, evaluated by flow cytometry at that time point suggested that MB-108-treated tumor regions exhibited T cell immune recruitment differences when compared to an untreated region, with increased numbers of CD3+ CD8+ effector T cells that express granzyme B and lower numbers of naive T cells. MB-109: Preclinical data from orthotopic GBM models in nude mice show that pre-treatment with MB-108 re-shaped the tumor microenvironment by increasing immune cell infiltrates, and the overall treatment with MB-109 gave no adverse reactions. These data also show that MB-109 combination therapy could be safely administered at low doses and leads to tumor shrinkage. An upcoming Mustang-sponsored Phase 1 clinical trial will evaluate the safety, tolerability, feasibility and preliminary efficacy of MB-109 in patients with IL13Ralpha2-positive relapsed or refractory GBM and anaplastic astrocytoma. Correlative studies will evaluate whether the combination approach can modify the tumor microenvironment, facilitate CAR T cell trafficking, and mitigate tumor immune escape by antigen loss.

10:04 EDT WooCommerce and Pinterest announce strategic partnership - WooCommerce and Pinterest announced a strategic partnership featuring an exchange of services they see "benefiting both companies and their users." The companies stated: "Built in partnership, the new, official Pinterest for WooCommerce extension available in the WooCommerce Marketplace allows mutual merchants to offer Pinterest shopping functionality directly from their Pinterest accounts. The integration enables over 3 million WooCommerce sellers to connect with Pinterest's 400 million monthly users. According to Pinterest data, 97% of the top searches on Pinterest are unbranded, which means browsers are within the discovery stage of their shopping journey. When they do purchase, Pinterest users spend two times more than people on other platforms."

10:03 EDT Neoleukin Therapeutics announces preclinical data for NL-201 - Neoleukin Therapeutics announced the presentation of preclinical data and a trial in progress overview for its immunotherapy candidate NL-201, an IL-2 and IL-15 agonist, at the American Association for Cancer Research Annual Meeting. Details of the poster presentations are as follows: NL-201, a de novo agonist of IL-2 and IL-15 receptors, demonstrates antitumor activity in preclinical B cell lymphoma models: NL-201 promotes in vitro cytotoxicity as a single agent and increases antibody-dependent cellular cytotoxicity in combination with anti-CD20 monoclonal antibody. NL-201 monotherapy demonstrates antitumor activity in the human Pfeiffer xenograft lymphoma model. NL-201 demonstrates robust monotherapy antitumor activity in the syngeneic murine A20 B cell lymphoma model and results in potent combination activity when NL-201 is combined with anti-PD-1 therapy. These findings support the evaluation of NL-201 in a planned clinical study in patients with B cell lymphomas and other hematological malignancies. NL-201, a de novo engineered IL2/IL15 mimic, synergizes with radiation to generate potent antitumor immunity: NL-201, in combination with radiotherapy, is well-tolerated in murine models and elicits robust antitumor activity through both innate and adaptive responses, including in checkpoint resistant tumors and brain metastases. NL-201 in combination with radiation therapy enhances activation of the cytosolic DNA sensor cyclic GMP-AMP synthase stimulator of interferon genes pathway. The immune mechanisms triggered by NL-201 plus radiation result in superior tumor growth inhibition and survival in both localized and metastatic murine breast cancers. Results support further investigation of this novel combination regimen in localized and metastatic cancers. A first-in-human Phase 1 study of NL-201 in patients with relapsed or refractory cancer: The multinational, first-in-human, open-label Phase 1 trial of NL-201 monotherapy is assessing the safety profile, recommended Phase 2 dose and treatment schedule in patients with advanced and/or refractory solid tumors. The primary objectives are to assess the safety and toxicity profile of NL-201 and define the recommended Phase 2 dose and treatment schedule. Enrollment is ongoing at sites in North America and Australia.

10:00 EDT BRC Inc. falls -6.6% - BRC Inc. is down -6.6%, or -$1.99 to $28.07.

10:00 EDT Gap rises 6.5% - Gap is up 6.5%, or 86c to $14.22.

10:00 EDT Ultrapetrol rises 96200.0% - Ultrapetrol is up 96200.0%, or $48.10 to $48.15.

09:56 EDT Studio City International Holdings Limited (Class A ADS) trading resumes

09:47 EDT Edenor falls -4.4% - Edenor is down -4.4%, or -30c to $6.50.

09:47 EDT Vertical Aerospace falls -14.4% - Vertical Aerospace is down -14.4%, or -$1.41 to $8.41.

09:47 EDT Charah Solutions rises 6.0% - Charah Solutions is up 6.0%, or 23c to $4.09.

09:36 EDT Lead Edge Growth Opportunities Ltd (Class A Stock) trading resumes

09:35 EDT Lakeside Book Company completes acquisition of Phoenix Color from ALJ - Lakeside Book Company announced that it has completed its acquisition of Phoenix Color Corp. from ALJ Regional Holdings. Phoenix is a specialty printer of book components, children's books, and other print-related products with printing facilities in Indiana and Maryland. In addition to book manufacturing, Lakeside provides distribution, sales and marketing services, as well as intellectual property and brand protection technology to book publishers. With this acquisition, Lakeside customers will have access to the most extensive portfolio of products, services, and solutions available in the industry. Phoenix will operate as a division of Lakeside Book Company. Dave McCree, Lakeside's CEO, will lead the combined business. Marc Reisch, former Executive Chairman of Phoenix, will support the business through the integration and remain with ALJ. Phoenix President John Carbone is retiring from the company as Phoenix begins this new era as a division of Lakeside.

09:30 EDT Citius Pharmaceuticals appoints Leonard Mazur as CEO, makes management changes - Citius Pharmaceuticals has approved key management changes aimed at strengthening the company's commercial capabilities as its two late Phase 3 programs for I/ONTAK and Mino-Lok near completion. The organizational alignment will be effective as of May 1. The Board of Directors has appointed current CEO Myron Holubiak to the newly created position of Executive Vice Chairman with responsibility for building the Citius commercial team and guiding the anticipated product launches of the company's first commercial products. Leonard Mazur, Citius co-founder and Executive Chairman has been named as CEO and Chairman. Additionally, CFO Jaime Bartushak will assume additional responsibilities as Chief Business Officer. Michael McGuire will join Citius as VP, Program Leader for Anti-Infectives effective May 1. While at Roche Laboratories, McGuire led the Tamiflu franchise to become the first billion-dollar product for Roche in the U.S.Most recently, McGuire was Senior VP Commercial, Government Affairs, and Customer Engagement at Melinta Therapeutics.

09:25 EDT SJW Group announces Maine Public Utilities Commission approval for Maine Water - SJW Group announced that a stipulation agreement between its Maine subsidiary, The Maine Water Company, and the Office of Public Advocate has been approved by the Maine Public Utilities Commission. The agreement stems from a general rate application linked to the company's $60M investment in a new drinking water treatment facility to serve Biddeford-Saco division customers.

09:20 EDT Heritage Commerce announces EVP Benito retires, Warford to succeed - Heritage Commerce announced the retirement of Executive Vice President, EVP, Michael Benito, effective June 1, 2022. At the same time, Dustin Warford will step in as Executive Vice President, Community Business Banking Division Manager, assuming Benito's responsibilities. Heritage Bank of Commerce also announced the promotions of Paul Perez to Real Estate Industries Division President and Doug Stewart to Market President for the Bank's Peninsula Region.

09:18 EDT Daqo New Energy provides update on Holding Foreign Companies Accountable Act - Daqo New Energy announced that it is aware of the fact that it was identified by the SEC under the Holding Foreign Companies Accountable Act of the U.S. - the "HFCAA" - on April 12. Such identification may have resulted from the company's filing of the annual report on Form 20-F for FY21. The identification indicates that the SEC determines that the company used an auditor, whose working paper cannot be inspected or investigated completely by the PCAOB, to issue the audit opinion for its financial statements for FY21. The company's ADSs will be delisted from the NYSE in early 2024, unless the Act is amended to exclude the company or the PCAOB is able to conduct a full inspection of the company's auditor during the required timeframe. The company has been exploring possible solutions.

09:18 EDT American Battery Metals hires McDaniel as Senior Staff Analytical Chemist - American Battery Technology continues expansion of its staff with new Senior Staff Analytical Chemist, Dr. Mark McDaniel. Dr. McDaniel joins ABTC with over twenty years of experience. Most recently, he worked with the Nevada Division of Environmental Protection, NDEP, as an environmental scientist in their Bureau of Water Quality Planning. In this new role, McDaniel will lead a team of scientists in the development and implementation of analytical procedures to quantify the quality and performance of materials within the lithium-ion battery recycling and primary lithium hydroxide manufacturing systems.

09:16 EDT Diana Shipping announces times charter contract with C Transport - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with C Transport Maritime, Bermuda, for one of its Newcastlemax dry bulk vessels, the m/v Philadelphia. The gross charter rate is US$26,000 per day, minus a 5% commission paid to third parties, for a period until minimum February 1, 2024 up to maximum April 15, 2024. The charter commenced yesterday. The "Philadelphia" is a 206,040 dwt Newcastlemax dry bulk vessel built in 2012. The employment of "Philadelphia" is anticipated to generate approximately $16.87M of gross revenue for the minimum scheduled period of the time charter.

09:14 EDT American Noble Gas enters into farmout agreement to explore Hugoton Gas Field - American Noble Gas announced it has agreed to acquire a 40% participation in a farmout agreement negotiated with a major operator relative to its existing oil and gas and brine interests in the Hugoton Gas Field in Haskell and Finney Counties, Kansas. AMGAS will join with three other partners to explore for and develop oil and gas and brine reserves on the property covered by the Farmout Agreement. The Farmout Agreement covers drilling and completion of up to 50 wells, with the first exploratory well scheduled to be spudded in April 2022. The Hugoton JV will utilize existing infrastructure assets, including water disposal, existing brine stream, gas gathering and helium processing, as part of the Farmout Agreement. The Hugoton JV also acquired the rights to all brine minerals produced, subject to a ten percent royalty, across all of Finney and Haskell Counties. The JV and its partners are currently developing proprietary technology with respect to brine mineral recovery which may be an important factor in efficiently harvesting the brine minerals produced under the Farmout Agreement. The first exploratory well is scheduled to commence in April 2022 near Garden City, Kansas with a goal to evaluate an unconventional theory for reinvigorating production from the Hugoton Gas Field. If the Hugoton JV is successful in proving out this theory, the Company anticipates that it could result in the unlocking of substantial gas and helium reserves embedded in the Hugoton Gas Field that were previously considered depleted.

09:13 EDT Lakeland Industries announces $5M stock repurchase program - Lakeland Industries announced that its Board of Directors has authorized a new stock repurchase program under which the Company may repurchase up to $5M of its outstanding common stock. This new program will become effective upon exhaustion of the current program which has approximately $800,000 remaining for repurchases. The new share repurchase program has no expiration date but may be terminated by the Board at any time.

09:11 EDT Molecular Partners announces shareholder approval of all board proposals at AGM - Molecular Partners announced that the shareholders of the Company approved all motions proposed by the Board of Directors. The shareholders of Molecular Partners voted to re-elect all members of Molecular Partners' Board of Directors for a term of office of one year. William "Bill" Burns was re-elected Chairman of the Board and re-appointed as the chairperson of the Board's Nomination and Compensation Committee. Steven Holtzman and Michael Vasconcelles, M.D., were also re-elected to the Nomination and Compensation Committee. KPMG AG Zurich was re-elected as the Group's statutory auditors for the financial year 2022 and Anwaltskanzlei Keller KLG, Zurich, elected as the independent proxy for a term of office until the 2023 Annual General Meeting. The shareholders of the company renewed the authorization of the Board of Directors of Molecular Partners AG to increase the share capital of the Company for a period of two years until April 13, 2024. The Annual General Meeting approved all binding motions regarding compensation of the Board of Directors and the Management Board. Further, the shareholders of Molecular Partners AG approved the annual report and the annual financial statements for the financial year 2021, the appropriation of the 2021 results, the appropriation of reserves, as well as the compensation report. The Board of Directors and the Management Board were granted discharge for the financial year 2021.

09:10 EDT Fat Brands' announces Quick-Service Division signed 20 new development deals - FAT Brands announces its Quick-Service Division has signed 20 new development deals, totaling over 50 additional units, following the acquisition of Global Franchise Group in June 2021. In total, there are over 150 units in the pipeline in the Quick-Service Division with over 30 locations set to open their doors in 2022. "While the pandemic has certainly impacted the restaurant space, we are so fortunate to have a deep store pipeline in addition to solid same-store-sales growth," said Jenn Johnston, President of FAT Brands' Quick-Service Division. "In the fourth quarter of 2021, same-store-sales within the division were up 10.6% in comparison to 2019 and up 16.1% in comparison to 2020. Since joining FAT Brands, we have increased our scale, offered franchisees access to new services, and have formed new synergies at both the brand and corporate level."

09:07 EDT Velo3D says Lockheed Martin uses its end-to-end additive manufacturing solution - Velo3D (VLD) announced Lockheed Martin (LMT) is using Velo3D's end-to-end additive manufacturing solution for its Additive Design & Manufacturing Center, which pilots new additive manufacturing technologies for production deployments in Lockheed Martin's Space division. Velo3D was selected for its advanced quality assurance capabilities made possible through its Assure software, which provides layer-by-layer traceability of machine health, part integrity, and build reporting. The solution Velo3D has delivered to Lockheed Martin includes a Sapphire printer, Velo3D's Flow print preparation software, its Assure quality assurance and control software, and its underlying Intelligent Fusion manufacturing process, which optimizes the additive manufacturing process by combining process simulation, geometry-based detection, and build process monitoring during print execution. This end-to-end solution gives customers the confidence that the mission-critical parts printed using Velo3D's additive manufacturing technology preserve design intent. It also provides customers with the ability to produce identical parts across any Velo3D Sapphire printer, so as production needs increase, customers can merely add additional printers to their production facilities anywhere in the world or utilize Velo3D's network of contract manufacturers. "The past few years have uncovered weaknesses in the global supply chain, which is causing many companies to evaluate new technologies to feed production of their mission-critical parts and hardware, and distribute their manufacturing processes," said Benny Buller, Velo3D CEO and Founder. "An additive manufacturing solution that can print identical parts anywhere you have a printer can not only help solve some very specific, complex challenges in our global supply chain, it can also lower production costs and lead times, and enable the manufacturing of parts in closer proximity to where they are needed." The company's latest Sapphire XC system enables higher productivity and lower production costs for Velo3D customers. It also enables the printing of parts that are 600 mm in diameter and up to 550 mm in height-500% larger than the previous Sapphire system

09:06 EDT Honeywell announces new sustainability commitments - Honeywell announced a new set of commitments that further advance its sustainability goals beyond the company's existing commitment to become carbon neutral in its facilities and operations by 2035. The new pledges include a commitment to develop a science-based target with the Science Based Targets initiative - SBTi - that includes scope 3 emissions and participation in the Department of Energy's Better Climate Challenge. The company also supports the Paris Climate Agreement. Honeywell will work with SBTi to reduce its emissions in line with climate science. Over the next two years, Honeywell will further quantify its Scope 3 emissions and work closely with SBTi to determine an appropriate reduction target for those emissions. Honeywell has already committed to carbon neutrality in Scope 1 and 2 emissions by 2035. Honeywell will reduce its Scope 1 and 2 emissions in the U.S. by 50% and improve energy efficiency by an additional 10% by 2030, from a 2018 baseline. As part of the Better Climate Challenge, Honeywell will develop a plan with greenhouse gas emissions reduction milestones, share its progress and solutions with other organizations, and report on its emissions data during the 10-year timeframe. About 60% of Honeywell's 2021 new product introduction R&D investment was directed toward ESG-oriented outcomes, and more than 60% of its 2021 sales were from offerings that contribute to ESG-oriented outcomes.

09:05 EDT Allogene Therapeutics publishes preclinical data on ALLO-316 - Allogene Therapeutics announced that new preclinical findings of ALLO-316, an AlloCAR T therapy targeting CD70 for the treatment of renal cell carcinoma, RCC, were presented in a poster session of the 2022 American Association for Cancer Research, AACR, Annual Meeting. The findings were also published in Cancer Research, a journal of the American Association for Cancer Research. CD70 has previously been shown to be highly expressed in RCC and several hematological cancers with limited normal tissue expression. The current work illustrates that CAR T cells targeting CD70 could be generated in which expression of CD70 CARs was found to mask the cells own CD70 receptors in cis, providing protection from CAR T-mediated fratricide. Multiple CAR T cell constructs were evaluated for anti-tumor activity against RCC cell line and patient-derived mouse tumor models. Lead candidates were evaluated in preclinical safety studies which indicated limited potential for off-target binding. Lastly, highly functional CD70 allogeneic CAR T cells that were gene-edited with TALEN to eliminate TCR expression were produced at large scale. "These results add to our strong interest in evaluating the potential of ALLO-316 to treat patients with CD70 expressing malignancies, including RCC and other cancers," said Rafael G. Amado, M.D., Executive Vice President of Research and Development and Chief Medical Officer. "Coupled with previously published preclinical data on ALLO-316 in a variety of tumors, these findings reinforce our belief that CD70 is an important target across a broad spectrum of cancers."

09:04 EDT New Relic achieves HITRUST certification for Its observability platform - New Relic has earned Certified status for information security by HITRUST. HITRUST Risk-based, 2-year Certified status demonstrates that the organization's New Relic One Platform hosted in Amazon Web Services has met key regulations and industry-defined requirements and is appropriately managing risk. This achievement places New Relic in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks, and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls. The certification follows the launch of New Relic's industry-first HIPPA-compliant observability platform, making it the first and only in the industry to attain these achievements for its full platform. By earning the HITRUST Risk-based, 2-year (r2) Certified status, New Relic meets industry-defined regulations to secure patient Protected Health Information (PHI) when managing telemetry data. As healthcare and life sciences organizations accelerated their digital transformation journeys during the COVID pandemic, Observability became business critical for them to ensure world-class digital experiences for their patients, providers and partners. However, adopting best-in-breed Observability practices has been a challenge for engineering teams, as most Observability solutions do not meet the required security and data protection regulations. The most difficult challenge has been around securing patient PHI. Today's launch helps overcome this critical challenge by ensuring that all of the telemetry data collected in New Relic including metrics, events, logs and tracesis part of a HIPAA-compliant and HITRUST Risk-based, 2-year Certified solution. "Our mission is to empower every engineer with observability. However, engineering teams in healthcare and life sciences organizations have traditionally not been able to widely adopt observability practices due to security and data protection regulations," said Wendy Sheppard, SVP & GM, Telemetry Data Platform. "To address this opportunity, we launched the industry's first HIPAA-compliant observability platform last year and are announcing the HITRUST Risk-based, 2-year Certification today. These milestones demonstrate our commitment to helping healthcare organizations deliver world-class experiences while keeping PHI secure."

09:03 EDT HUMBL selected to pilot digital wallet program with County of Santa Cruz, CA - HUMBL announced the unanimous approval and formation of a pilot program with the County of Santa Cruz, California, CA, to develop a digital wallet. The program will be customized at the request of the County to experiment with the streamlining and equitable distribution of city services to all of its constituents via mobile wallet. The initial pilot program will include the infrastructure for a digital wallet and expanded to serve the needs of the community as the County sees fit. The initiative was sponsored by Supervisor Zach Friend and approved unanimously by the County Board of Supervisors in their meeting on April 12, 2022. The program will be delivered and reported back on no later than August 9, 2022. "At HUMBL Blockchain Services we believe one of the key uses of blockchain will be mobile wallets. Delivering personal identification, verifiable credentials, document storage and payment methods for citizens around the world to interact more effectively with their local, state and national governments," said HUMBL CEO, Brian Foote. "Today is a positive step towards that future here in the United States and in our home state of California."

09:02 EDT NGM partners with First Solar Technology to decarbonize energy supply - First Solar (FSLR) announced that its responsibly-produced photovoltaic, PV, solar module technology would power 17 percent of the annual energy needs of Nevada Gold Mines, NGM. NGM is a joint venture between Barrick Gold Corporation (GOLD) and Newmont Corporation (NEM) that is operated by Barrick. As part of the deal, which was booked prior to the release of First Solar's Q4 and Full Year 2021 earnings in February, 260 megawatts DC of solar modules manufactured by First Solar in Ohio will be deployed to power the new 200 MWAC facility in the second quarter of 2023. "As America's solar company, we're proud to support Nevada Gold Mines with responsible solar technology designed and developed right here in the United States," said Georges Antoun, chief commercial officer, First Solar. "NGM is part of a growing wave of customers that are unwilling to compromise on quality or their principles, and choose to partner with First Solar. They partnered with us because we can deliver a high-performance module that comes without the social, environmental, and political risks that are, unfortunately, associated with too many solar manufacturers today."

09:00 EDT JPMorgan sees modest growth in deposits as base case

08:54 EDT Bed Bath & Beyond says 'very happy' with financial performance of BuyBuy Baby - Says working to unlock "full potential" of Baby unit.

08:44 EDT JPMorgan will provide updates to financial targets next month, says CFO - JPMorgan is set to hold its investor day event in May, CFO Barnum says.

08:43 EDT Power Solutions' 6.0-liter industrial mobile engine receives EPA certification - Power Solutions International announced that the U.S. Environmental Protection Agency and California Air Resources Board have certified the company's 6.0-liter gasoline-powered industrial mobile engine. The certifications cover mobile, non-road emission regulations for constant speed operation. The 6.0-liter industrial mobile engine is a fully integrated drop-in solution delivering uncompromised power performance and maximum fuel efficiency. The engine delivers 174-horsepower of power at 2900 rpm and peak torque of 315 ft-lbs. at 2900 rpm.

08:41 EDT Greenlane appoints Darsh Dahya as CAO - Greenlane Holdings (GNLN) announced the appointments of Darsh Dahya as Chief Accounting Officer, effective April 18, 2022, and Renah Persofsky as Board Director, effective April 11, 2022. The Company also announced the resignation of Dallas Imbimbo from the Company's Board of Directors. Dahya previously served as the Senior Vice President of Accounting at MedMen Enterprises (MMNFF), a leading cannabis retailer with operations across the nation. As Chief Accounting Officer, Mr. Dahya will lead many of Greenlane's principal financial activities. The Company has appointed Renah Persofsky as a Board Director. Ms. Persofsky has served as the Chief Executive Officer of Strajectory Corp. since 2010 and was an Executive Consultant of Canadian Imperial Bank of Commerce from 2011 to 2021. The Company also announced that Dallas Imbimbo, Chairman of the Nominating and Corporate Governance Committee, has resigned from the Company's Board of Directors to pursue other business interests. A serial entrepreneur, Mr. Imbimbo was a founder of Kush Bottles and later KushCo Holdings, which merged with the Company in 2021.

08:37 EDT Bed Bath & Beyond says seeing 'challenging' sales, traffic trends in Q1 - Sees negative adjusted EBITDA in Q1. Says will continue to mange cost structure "prudently." Expects "modest" gross margin expansion in FY22.

08:36 EDT Navios Maritime Partners announces availability of 2021 Form 20-F - Navios Maritime Partners announced that its Annual Report on Form 20-F for the year ended December 31, 2021 has been filed with the SEC and can be accessed on Navios Partners' website www.navios-mlp.com under the "Investors" section.

08:35 EDT Nuvectis Pharma provides highlights from presentations on NXP900 - Nuvectis Pharma provided highlights from the poster presentation of NXP900 that took place yesterday at the American Association for Cancer Research Conference in New Orleans. NXP900 Poster Presentation Key Highlights: Novel mechanism of action locks the target kinase in its closed confirmation, resulting in inhibition of both the catalytic and scaffolding functions ot the target. High selectivity demonstrated in a comprehensive kinome screen. Clinically relevant mechanisms of sensitivity identified. High sensitivity in various types of cancer cell lines of squamous origin. FAT1 loss-of-function mutations, which are highly prevalent in squamous carcinomas, in particular in head & neck, is associated with sensitivity to NXP900. IND-enabling studies ongoing.

08:34 EDT JPMorgan continuing to see positive trends in loan growth, CFO Barnum says - Comments taken from Q1 earnings conference call.

08:34 EDT Oncternal Therapeutics expects cash runway well into 3Q23 - Estimated $82.2 million in cash and cash equivalents and no debt as of March 31, 2022

08:32 EDT Oncternal Therapeutics deprioritizes development of ONCT-216 - Oncternal Therapeutics announced that it has deprioritized further development of ONCT-216 to reallocate resources to zilovertamab, the Company's investigational anti-ROR1 monoclonal antibody, and its Phase 3 registrational trial that the Company expects to initiate in Q3 2022. As such, the Company has discontinued enrollment in the Phase 1/2 study evaluating ONCT-216 in patients with relapsed or refractory Ewing sarcoma. The Company expects to initiate its global registrational Phase 3 Study ZILO-301 in the third quarter of 2022, taking into account the impact of geopolitical factors and COVID-19 related supply chain issues. The study will randomize patients with relapsed or refractory MCL who have experienced stable disease or a partial response after receiving four months of oral ibrutinib therapy to receive either blinded zilovertamab or placebo, and all patients will continue receiving oral ibrutinib. The novel ZILO-301 design is supported by encouraging data from the Company's ongoing Phase 1/2 clinical trial of zilovertamab plus ibrutinib for patients with MCL or CLL, as well as by a successful End-of-Phase-2 meeting with the U.S. Food and Drug Administration. The Company's lead autologous ROR1-targeted CAR-T cell therapy program candidate, ONCT-808, is advancing according to plan towards an Investigational New Drug application submission expected in mid-2022, based on supportive manufacturing and preclinical data as well as a productive pre-IND meeting with the FDA earlier this year. Finally, the Company continues to advance ONCT-534, its lead candidate in its DAARI program, and expects to initiate IND-enabling GLP toxicology studies and GMP manufacturing later this quarter. ONCT-534 has shown anti-tumor activity in preclinical studies relevant to multiple clinically important forms of resistance for patients with prostate cancer, including those involving overexpression of the androgen receptor, or expression of mutants of the androgen receptor, or splice variants such as AR-V7.

08:31 EDT Artelo Biosciences reports results for program on ART27.13 - Artelo Bioscience announced that ART27.13, a peripherally selective G-Protein Coupled Receptor, GPCR, full agonist currently in clinical development for cancer-related anorexia, shows promising pre-clinical results in protecting human muscle cells from cancer-induced muscle degeneration via a CB2 mediated mechanism of action. "These exciting early results demonstrate that ART27.13 is capable of reducing negative effects of chemicals produced by multiple cancers on human muscle fibers," added Saoirse O'Sullivan, Ph.D., Vice President Translational Science, Artelo Biosciences. "We look forward to seeing how these results may translate into the ongoing CAReS study currently in the final stages of enrolling cohort 3 at six clinical trial sites in the United Kingdom and Ireland."

08:29 EDT Neovasc reports results of annual general, special meeting of shareholders - Neovasc is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on April 12, 2022 in Vancouver, B.C.. At the Meeting, the shareholders of the Company re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko and Fred Colen to serve in office until the next annual meeting or until their successors are duly elected or appointed. At the Meeting, the Shareholders also approved the Company's common share consolidation and appointed Grant Thornton, Chartered Accountants as auditors of the Company.

08:27 EDT Pineapple Holdings changes name to Pineapple Energy - Pineapple Holdings, which was formerly Communications Systems and changed its name when completing the merger with Pineapple Energy announced that it changed its legal name to Pineapple Energy, effective immediately. All other information about the Company, such as its headquarters address, remain unchanged. Pineapple continues to trade on the Nasdaq Capital Market under the symbol "PEGY."

08:20 EDT 22nd Century launches national pilot of VLN cigarettes - 22nd Century developed VLN cigarettes containing 95% less nicotine than conventional cigarettes. The proprietary tobacco was the subject of 10 years of research and more than 50 government-funded, independent clinical trials. The research found: A 50% reduction of cigarettes per day after 20 weeks; More smoke-free days and quit attempts; and a reduction in cravings and withdrawal symptoms. As a result of these and other scientific evidence, VLN received the FDA's first and only modified risk tobacco product authorization granted for a combustible tobacco cigarette. Michael Zercher, president & chief operating officer of 22nd Century Group, said the company is focused on harm reduction and plant technology/science and not affiliated with the "big tobacco" companies. "More than 30 million Americans still smoke despite decades-long attempts to migrate smokers to other forms of nicotine delivery, taxing cigarettes, banning public smoking, and numerous education campaigns about the dangers of smoking," Zercher said. "22nd Century Group is the only company approaching the problem by removing the addictive element from combustible cigarettes, an approach the FDA projects could save 8 million lives by the end of the decade if the nicotine levels of all cigarettes were to be reduced to the levels achieved by VLN."

08:18 EDT Praxis Precision Medicines to host Epilepsy Day on April 27 - Praxis Precision Medicines announced that the Company will host an Epilepsy Day from 8:30 a.m. to 11:30 a.m. ET on Wednesday, April 27, 2022 virtually and in New York City. During the event, Praxis' management team will review the Company's Epilepsy franchise, one of its three franchises in addition to Psychiatry and Movement Disorders. The Epilepsy Day will include a review of Praxis' epilepsy programs, which together make up the largest pipeline of epilepsy drug candidates in the industry, a discussion on the clinical and regulatory paths forward for these programs and a look into how genetics is elucidating new epilepsy targets for Praxis. Praxis' management team will be joined by the following key opinion leaders, who will highlight how recent advancements in the understanding of epilepsy biology and drug development have the potential to address the tremendous unmet need of people living with epilepsy: Jacqueline French, M.D., Professor of Neurology at NYU Grossman School of Medicine and President, Director & Founder of the Epilepsy Study Consortium; Daniel Friedman, M.D., MSc., Professor of Neurology at NYU Grossman School of Medicine and Co-Director, Video-EEG Laboratory at NYU Langone Health.

08:16 EDT Freshworks expands partnership with Device42 - Freshworks announced that it has deepened its strategic partnership with Device42, the market leader in asset management, to give Freshservice customers enterprise-grade asset management for enhanced business continuity. "We're now used to hybrid working environments with distributed IT teams, meaning the need for platforms that can deliver high service availability and reliability for employees is critical for digital transformation," says Prakash Ramumurthy, Chief Product Officer at Freshworks. "Freshservice combined with Device42 means an ITSM solution to enable IT services and operations teams to keep business-critical services always on." Using Device42 with Freshservice provides customers with real-time information about complex infrastructure and their relationships for high-precision service management and delivery.

08:15 EDT Climb Channel Solutions expands Seagate technology offerings - Climb Channel Solutions, a wholly-owned subsidiary of Wayside Technology Group, Inc. (WSTG), in collaboration with Seagate Technology Holdings (STX), is expanding its data protection and storage portfolio to provide Seagate's Lyve Mobile to the channel community. Lyve Mobile data transfer services are designed to address these top challenges, enabling secure, cost-effective means to rapidly move massive volumes of data across their enterprises. The latest collaboration between Climb and Seagate enables solution providers to accelerate their clients' time to data, bringing data transfer as-a-service to the channel community which will allow for new revenue opportunities for partners. Lyve Mobile is a key enabler for solving clients' data mobility challenges. By providing an agnostic tool for edge-to-core data workflows, Lyve Mobile enables hardware, software, and managed services opportunities behind its subscriptions. The collaboration between Climb and Seagate Lyve Mobile enables Solution Providers access to the Lyve Mobile Services through a trusted channel provider. Lyve Mobile fits nicely into Climb's portfolio and is expected to enable the channel community to continue to provide value and services unique to the enterprise market's needs.

08:13 EDT Cybin says CYB004 data demonstrates advantages over intravenous/inhaled DMT - Cybin announced positive preclinical data from a pharmacokinetic study evaluating its proprietary deuterated dimethyltryptamine molecule, CYB004, delivered via inhalation. Specifically, inhaled CYB004 demonstrated significant advantages over both IV DMT and inhaled DMT, including longer duration of action, and improved bioavailability. The study also demonstrated that inhaled CYB004 showed a similar onset of effect and dose profile to IV DMT. These data may support the potential for inhalation as a viable and well-controlled delivery system of therapeutic psychedelics. Cybin is currently developing CYB004 for the treatment of anxiety disorders. "In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues. However, known side effects like disorientation and anxiety and its mode of administration have historically hindered its use and availability. CYB004 via inhalation may solve these challenges and finally support a clinical path forward for this important therapeutic. As part of Cybin's overall mission to create safe and effective psychedelic-based therapeutics, inhaled CYB004 is being developed to potentially overcome the limitations of IV DMT and become an important treatment option for anxiety disorders for patients and physicians," said Doug Drysdale, Chief Executive Officer of Cybin.

08:12 EDT Aquestive announces common stock purchase agreement up to $40M - Aquestive Therapeutics announced it has entered into a common stock purchase agreement for up to $40M with Lincoln Park Capital Fund. Under the terms of the purchase agreement and registration rights agreement, Aquestive will have the right in its sole discretion, but not the obligation, to sell to LPC up to $40M worth of shares of its common stock over the 36-month term of the agreement. Aquestive controls the timing and amount of any future sales of its shares of common stock and LPC is obligated to make purchases in accordance with the purchase agreement, subject to various limitations including those under the Nasdaq listing rules. Any common stock that is sold by Aquestive will occur at a purchase price that is based on the market prices prevailing at the time of each sale to LPC. There is no upper limit to the price per share that LPC may pay for future stock issuances under the purchase agreement, and LPC has agreed not to cause or engage in any direct or indirect short selling or hedging of Aquestive's common stock. No warrants are being issued in this transaction and the purchase agreement does not contain any rights of first refusal, participation rights, penalties or liquidated damages provisions in favor of any party. Aquestive may terminate the purchase agreement at any time, at its sole discretion, without any cost or penalty. Aquestive intends to use the net proceeds from the sale of its common stock under the purchase agreement for working capital and general corporate purposes to support its growth.

08:11 EDT Lineage Cell announces Cancer Research UK completes enrollment for VAC2 trial - Lineage Cell Therapeutics announced that Cancer Research UK recently completed patient enrollment in the ongoing Phase 1 clinical trial of VAC2, an allogeneic cancer vaccine product candidate, for the treatment of non-small cell lung cancer, or NSCLC. Under the terms of an existing agreement, Cancer Research UK will complete the ongoing clinical trial and Lineage has now assumed responsibility for further clinical development of the VAC2 product candidate and any future development opportunities derived from the VAC platform.

08:10 EDT DatChat announces opening of metaverse corporate headquarters - DatChat announced that it will be opening corporate headquarters and Venvuu demo centers in eight metaverses. DatChat also confirmed its 5,000 Venvuu Dynamic Content NFTs will go on sale Monday, May 9, 2022, after previously opening pre-sale registration on March 28. The Sandbox, Decentraland, Somnium Space, Cryptovoxels, Cornerstone Land, House of Kibaa, TCG World and SuperWorld are the listed metaverses, and of these, Cryptovoxels and Decentraland are currently open, and where DatChat's Venvuu technology demo centers can be visited. "We are excited to have solidified our presence in the Metaverse and believe our occupancy in each of the 'Big Four' enables us to become a pioneer in the monetization of metaverse parcels and NFTs," said DatChat CEO Darin Myman. "The technology demo centers in both Cryptovoxels and Decentraland are currently open for viewing our Venvuu platform technology."

08:07 EDT Longeveron enters into CRADA with US Department of VA - Longeveron announced a Cooperative Research and Development Agreement, CRADA, with the United States Department of Veterans Affairs, VA, for the addition of a Miami VA clinical site to its ongoing Phase 2 Alzheimer's Disease, AD, trial. As recently reported in a peer reviewed article in Alzheimer's & Dementia, The Journal of the Alzheimer's Association, Longeveron's Phase 1 trial met its primary endpoint, demonstrating that its drug Lomecel-B was well tolerated in Alzheimer's patient. "After meeting the rigorous requirements of the VA, we are pleased to announce the addition of this particular Miami VA site to our ongoing trial," said Geoff Green, Chief Executive Officer at Longeveron. "This continued collaboration between Longeveron and the Miami VA reflects our ongoing efforts to develop a safe and effective cell-based therapy for this devastating disease in the vital setting of the VA health system." This marks the third separate CRADA agreement between the VA and Longeveron, including an Aging Frailty study and an ongoing study on Covid-19.

08:07 EDT Clear Secure launches expedited lanes at Ontario International Airport - Clear Secure launched its expedited lanes in both terminals at Ontario International Airport. ONT is Clear's sixth airport in California and 41st across the U.S.; CLEAR already serves all 10 of ONT's top 10 domestic destinations. Members use Clear's network of dedicated lanes to verify their identity with their eyes. Clear Plus is an opt-in membership that provides access to Clear's expedited security lanes.

08:05 EDT Applied Molecular Transport announces publication on AMT-101, AMT-126 - Applied Molecular Transport announced that new insights into the unique mechanism of action utilized by its oral biologic product candidates, including lead clinical programs AMT-101 and AMT-126, have been published in Tissue Barriers. Oral AMT-101 and AMT-126 are in development to treat diseases associated with immune dysregulation and intestinal epithelial barrier defects, such as ulcerative colitis, pouchitis and rheumatoid arthritis. The article, entitled "GRP75 as a Functional Element of Cholix Transcytosis," was published in the online edition of Tissue Barriers. "We are excited to share additional insights into our breakthrough platform technology, which enables active transport of oral biologics across the intestinal epithelial barrier," said Randall Mrsny, PhD, chief scientific officer and co-founder of AMT. "Specifically, the interactions between the cholix carrier and intracellular elements, including GRP75, play a critical role to efficiently traffic our oral biologics through a privileged and protected pathway into the intestinal lamina propria. The elucidation of this unique pathway enables application of our technology platform to a wide range of intra- and extracellular disease targets in mucosal immunology and other therapeutic areas."

08:05 EDT Atlas Corp.'s APR Energy extends gas generation contract in Brazil - APR Energy, a wholly-owned subsidiary of Atlas Corp., announced that it has extended its previously announced 12-month gas generation contract in Brazil to a 226 MW 44-month contract. The extension furthers APR Energy's growth strategy of providing longer-term energy capacity solutions.

08:04 EDT BriaCell receives FDA Fast Track approval for Bria-IMT - BriaCell Therapeutics announces that the U.S. Food and Drug Administration, FDA, has granted Fast Track status to BriaCell's lead candidate, Bria-IMT, for the treatment of metastatic breast cancer. The Fast Track designation will apply to patients with metastatic breast cancer. BriaCell is developing Bria-IMT in combination with immune checkpoint inhibitors. Initial data on patient survival in this study was first presented at the San Antonio Breast Cancer Symposium in December 2021 and was over 12 months compared with 7-10 months in a study in 3rd line breast cancer patients. "We are grateful for the opportunity to accelerate the development of our novel immunotherapy in advanced breast cancer. We continue to move forward with the clinical evaluation of Bria-IMT(TM) towards a potential registration study to bring hope to patients living with this deadly disease," said Dr. Del Priore, BriaCell's Chief Medical Officer.

08:04 EDT Hasbro to acquire D&D Beyond for $146.3M in cash from Fandom - Hasbro announced that it is acquiring D&D Beyond, the digital toolset and game companion for the company's fantasy franchise, Dungeons & Dragons, from Fandom. Fandom has owned and operated D&D Beyond since 2019. This acquisition, for $146.3M in cash, will further aid Hasbro's capabilities in the digital tabletop category. Since 2017, D&D Beyond has helped to power Dungeons & Dragons tabletop play and deliver the brand's eighth consecutive year of growth in 2021. Over the last three years, the royalty paid to Hasbro by D&D Beyond has represented a contribution to the source of revenue for Dungeons & Dragons. The transaction is subject to customary closing conditions and the receipt of certain regulatory approvals, and is expected to close during the second or third quarter of 2022. The transaction will be funded out of cash on hand and is expected to be immaterial to revenue and earnings per share in 2022 and accretive to earnings per share in fiscal year 2023 and beyond. The transaction has been approved by both Hasbro's and Fandom's boards of directors.

08:03 EDT ViaSat's in-flight connectivity system granted Airbus A320 validation in China - Viasat has been awarded a Civil Aviation Administration of China Validation of Supplemental Type Certificate to install its Ka-band satellite system on Airbus A320 series of aircraft. This CAAC validation, Viasat's first in China, lays the foundation for Chinese airlines to install and deploy Viasat's In-Flight Connectivity system, including antenna, radome, modem, server and WAPs, on Airbus A320s. The CAAC VSTC was awarded based on an Airbus A320 STC previously certified by the European Union Aviation Safety Agency.

08:02 EDT Lowe's announces debt-free education programs for associates - Lowe's announced a new education program to make it easier for associates to grow their careers. The new benefit gives full-time and part-time associates access to 100 percent debt-free programs, unlocking opportunities for over 300,000 eligible associates to pursue their educational and career aspirations. In partnership with Guild, Lowe's is offering over 50 academic programs across 23 universities and learning providers in Guild's Learning Marketplace, including Historically Black Colleges and Universities and Hispanic-Serving Institutions. The free programs are designed to help associates excel in their jobs today and build toward the careers of tomorrow within Lowe's, including pathways into supply chain, logistics, data analytics, cybersecurity, technology and more.

07:57 EDT Texas city selects BIO-key's PortalGuard IAM platform - BIO-key International announced that a Texas city has selected its PortalGuard IAM platform, with support for a broad array of multi-factor authentication options, to protect its enterprise applications and data. Leveraging the PortalGuard IAM platform, the municipality can strengthen its overall security posture and effectively respond to evolving cyber threats. This new customer relationship, BIO-key's first with a Texas municipality, was secured by Dallas-based IT consulting firm Mejeticks through BIO-key's master agent Intelisys.

07:55 EDT Fastenal reports March sales up 19.1% to $632.63M - The company reported March sales of $632.63M versus $531.37M in the same month of last year. Fastenal reported March daily sales of $27.51M, up 19.1% versus 2021. Reference Link

07:51 EDT Bed Bath & Beyond sees FY22 CapEx $400M - Sees FY22: Depreciation & amortization approximately $260M; Store openings approximately 20-25 (primarily BABY); Store remodels approximately 130-150 (primarily Bed Bath). Liquidity remains healthy, including $1B ABL revolver.

07:46 EDT Bed Bath & Beyond says Q1 SSS QTD trend negative low-20s - In Q1, expects: Cost inflation headwinds to persist, not fully offset by pricing; Slightly lower adjusted SG&A spend vs. LY, albeit deleverage due to sales decreases; Negative adjusted EBITDA; $40M of share repurchases, $1B program to be completed. Comments taken from investor presentation slides for Q4.

07:40 EDT Ferrari announces results from Annual General Meeting - Ferrari announced that all resolutions proposed to Shareholders at the Ferrari's Annual General Meeting of Shareholders held virtually were passed. The Shareholders approved the 2021 Annual Accounts, expressed a positive advice with respect to the Remuneration Report 2021 and approved a dividend in cash of Euro 1.362 per outstanding common share, totalling approximately Euro 250 million. The outstanding common shares will be quoted ex-dividend from April 19, 2022. The record date for the dividend will be April 20, 2022 on both EXM and NYSE and the dividend on the outstanding common shares will be paid on May 6, 2022. Shareholders holding the Company's common shares on the record date that are traded on the NYSE will receive the dividend in U.S. dollars at the official European Central Bank EUR/USD exchange rate of April 14, 2022. The AGM appointed all Ferrari directors standing for election. John Elkann and Benedetto Vigna were elected as executive directors of Ferrari. Piero Ferrari, Delphine Arnault, Francesca Bellettini, Eduardo Cue, Sergio Duca, John Galantic, Maria Patrizia Grieco and Adam Keswick were elected as non-executive directors of Ferrari. In addition, the Shareholders appointed Ernst & Young Accountants LLP as Ferrari's independent auditor for 2022 financial year until the 2023 Annual General Meeting of Shareholders and the AGM appointed Deloitte Accountants B.V. as Company's independent auditor for 2023 financial year from the 2023 Annual General Meeting of Shareholders until the 2024 Annual General Meeting of Shareholders. The AGM renewed the existing delegations to the Board of Directors of the Company of the authority to issue common and special voting shares, to grant rights to subscribe for common and special voting shares, and to limit or exclude pre-emptive rights for common shares, subject to certain maximum amount thresholds. Furthermore, the AGM renewed, for a period of 18 months from the date of the AGM, the existing authorization of the Board of Directors to repurchase up to a maximum of 10% of the Company's common shares issued as of the date of the AGM. Pursuant to the authorization, which does not entail any obligation for the Company but is designed to provide additional flexibility, the Board of Directors may repurchase common shares in compliance with applicable regulations, subject to certain maximum and minimum price thresholds. The Shareholders further approved the awards of common shares in the capital of the Company to the executive directors.

07:36 EDT Bed Bath & Beyond reports Q4 adjusted gross margin 28.8% - Compared to 32.8% a year ago. Adjusted Gross Margin reflects decline of 400bps vs. Q4 2020 primarily due to product cost increases of 40 basis points net of product, pricing and promotional optimization, as well as 360 basis points primarily related to transient port fees and freight and shipping inflation. Freight and shipping cost increases included unexpected, higher than anticipated inflation of 170 basis points, first-time port-related fees of 100 basis points, and warehouse-related inventory adjustments of 90 basis points as year finalized. Excluding the aforementioned supply chain costs escalations, Q4 Adjusted Gross Margin of 32.4%.

07:33 EDT iSpecimen adds Acutis Diagnostics to marketplace platform - iSpecimen announced that it added Acutis Diagnostics, a clinical diagnostics laboratory, to its platform as a laboratory services provider. Through the Acutis relationship, iSpecimen will now offer sequencing services to its research community that can help researchers better understand genetic mutations and their impact on diseases. "Adding Acutis to the iSpecimen Marketplace ecosystem enables the platform to become even more of a full-service, one-stop-shop for researchers looking to find highly sought-after samples and genetic information for their medical research," added Dr. Christopher Ianelli, M.D., Ph.D., iSpecimen Founder and CEO. "iSpecimen continues to prioritize expanding its proprietary network and platform to ensure that researchers all over the world can easily obtain invaluable biospecimen samples necessary to propel their work forward."

07:32 EDT Bed Bath & Beyond sees sequential SSS improvement in 2H22 - At this time, the company is providing the following outlook parameters for fiscal 2022: Sequential Comparable Sales improvement to occur in the second half of fiscal 2022 versus the first half of fiscal 2022 based on anticipated improvement in supply chain conditions; Adjusted Gross Margin to expand modestly versus last year based on improvement in the second half of fiscal 2022; Adjusted SG&A expense approximately flat to last year; $100M optimization plan aims to offset inflation as previously announced; Higher Adjusted EBITDA versus last year for the second half of fiscal 2022 based on the aforementioned Comparable Sales and Adjusted Gross Margin commentary.

07:32 EDT Iris Energy announces commissioning of first 0.3 EH/s at Mackenzie, BC - Iris Energy announced it has increased its operating hashrate by 33% to exceed 1.1 EH/s of total installed capacity with the commissioning of the first 0.3 EH/s at its second site, in Mackenzie, BC Canada. The commencement of operations at Mackenzie marks the delivery of the Company's second operating site in BC, Canada ahead of schedule, as Iris Energy continues its expansion towards 15 EH/s of total installed capacity across multiple sites. Construction activities at Mackenzie continue to progress to schedule with phase two, the balance of the initial 1.5 EH/s, expected to come online in Q3 2022, and phase three for the additional 0.9 EH/s for installed capacity of 2.4 EH/s expected in 2023.

07:23 EDT Sapiens selected by Hollard Insure for large-scale digitalization program - Sapiens has expanded its relationship with the Hollard Insurance Company to empower Hollard's strategic digital drive with Sapiens cloud-native, low-code DigitalSuite. The large-scale modernization is aimed at digitizing products and journeys through a low-code, digital front-end with strong integration capabilities.

07:21 EDT 9 Meters Biopharma announces allowance of patent for NM-136 - 9 Meters Biopharma announced that the Company has received notice from the United States Patent and Trademark Office that U.S. Patent Application No. 16/781,304 is allowed. The patent provides protection for the use of NM-136 for the treatment of hyperphagia, serious metabolic conditions such as obesity, and for reducing fatty tissue buildup in body organs. NM-136 is a long-acting, highly specific humanized anti-GIP monoclonal antibody. NM-136 has been shown to prevent glucose-dependent insulinotropic polypeptide from binding to its receptor, which in preclinical obesity models has been shown to significantly decrease weight and abdominal fat by reducing nutrient absorption from the intestine as well as nutrient storage without affecting appetite.

07:17 EDT Lifeist's Mikra adds Ashley Wagner, Cullen Jones as brand ambassadors - Lifeist Wellness announced its wholly owned U.S. subsidiary, Mikra Cellular Sciences has engaged Olympic medalists Ashley Wagner and Cullen Jones as Brand Ambassadors. Ashley Wagner is a bronze medalist in figure skating at the 2014 Sochi Winter Olympics and a silver medalist at the 2016 World Championships. Cullen Jones is a gold medalist in swimming at the 2008 Olympic Games in the 4x100m freestyle, and won two silvers and a gold in the 4x100m medley relay at the 2012 Olympic Games.

07:16 EDT ProQR Therapeutics announces additional sepofarsen Illuminate trial analyses - Following the top-line announcement in February 2022 that Illuminate, ProQR's pivotal Phase 2/3 trial of sepofarsen in CEP290-mediated LCA10, did not meet the primary endpoint of Best Corrected Visual Acuity at Month 12 compared to a sham procedure control group, comprehensive post-hoc analyses of the trial were undertaken which revealed: No technical errors in the trial conduct, data handling, or the drug product used. The overall safety profile of sepofarsen was consistent with earlier trials. When the effect in the treatment eye was compared to the untreated contralateral eye in the same patient, at Month 12, a benefit in vision was observed as a mean change from baseline in BCVA of -0.12 logMAR in the sepofarsen treated groups. This effect was not observed in the sham treated group with the same comparison. Other endpoints showed similar effect when comparing treatment to contralateral eye, including Full Field Stimulus Testing. These findings were supported by the patient reported outcomes analyses, based on the Patient Global Impressions-Change that demonstrated that 61% of patients in the treatment groups reported an improvement in vision, as well as by Visual Function Questionnaire 25. Overall, the post-hoc analyses showed that the efficacy signal seen with sepofarsen when comparing active treatment and sham eyes to their corresponding contralateral eyes across BCVA, FST, and other endpoints, including PROs, was more consistent with the results seen in earlier findings, where the contralateral eye was used as the control. Based on these results, ProQR will focus on the following core activities related to sepofarsen: In Q3, the Company plans to meet with the EMA and FDA to discuss these data from the Illuminate trial. Following this discussion, ProQR will share an update in Q3 or early Q4, depending on timing of regulatory meetings. Based on the recommendation of the Data Safety and Monitoring Committee, the Company currently plans to continue Illuminate, which is a 2 year study, the Brighten pediatric study, and Insight, until further regulatory guidance, after which next steps will be determined. No further investments are planned at this time for new trials of sepofarsen or commercial preparations. Data from the Illuminate trial will be presented at the upcoming Seventh Annual Retinal Cell and Gene Therapy Innovation Summit, April 29, 2022, and the Association for Research in Vision and Ophthalmology Annual Meeting, May 1-4, 2022.

07:14 EDT Osino Resources announces updated mineral resource for Twin Hills project - Osino Resources announces an updated mineral resource for its Twin Hills Gold Project in the Erongo Region of Namibia. The Company's previous resource announced in July of 2021, has grown substantially along with significant conversion of Inferred resources to Indicated resources. The increase in resources is due to resource expansion in the Twin Hills Central, Bulge and Clouds areas, and delineation of additional resources from new areas. The mineral resource was estimated from approximately 167,000m of diamond core, DD, and reverse circulation, RC, drilling, of which approximately 153,000m has been sampled with available assay data. Heye Daun, Osino's President & CEO commented: "We are very pleased with the results of the intensive 2021 drill program which resulted in this significant increase in Osino's mineral resources at Twin Hills with total indicated mineral resources having increased more than 4-fold. Likewise, the higher-grade portion of the Indicated mineral resource above a cut-off grade of 0.9 g/t has also significantly increased by about 4.5x to 32.9 Mt at 1.27 g/t. Especially the Clouds and more recent Twin Hills West discoveries have contributed a significant amount to the resource and have extended the mineralized strike of the Twin Hills gold system to more than 3.5km. Additional new mineralized lobes at Twin Hills North and Clouds West have also contributed further resources and will be followed up."

07:12 EDT ProQR Therapeutics to reduce workforce by 30%, CSO Naveed Shams to depart - The company will reduce the workforce by approximately 30%, which will include the departure of our Chief Scientific Officer Naveed Shams, MD, PhD, expected to be effective in Q2.

07:12 EDT WeWork and Yardi team on next generation of workplace software - WeWork announced WeWork Workplace product. By partnering, the two organizations will provide companies of all sizes with a universal platform for powering and optimizing flexible workplace strategies. The rapid adoption of the flexible hybrid work model has forced businesses to rethink and optimize their office and space utilization strategies with an emphasis on creating a more seamless and purposeful employee experience. The partnership will merge Yardi's industry-leading software and tech capabilities with current WeWork Workplace booking capabilities to create a software solution tailored for corporate enterprise users. This enhanced WeWork Workplace product, set to launch in July 2022, will help facilitate this transition and enable companies to offer their employees the ability to seamlessly book a desk, private office or conference room in any company-leased or owned office space, any WeWork location, or any affiliate of WeWork. For almost 40 years, Yardi has provided integrated property management software and solutions to landlords, investors, owners and operators. As a result, this partnership will marry Yardi's industry-leading software and tech capabilities with WeWork's global member network of more than 26,000 small and medium-sized businesses and 2,300 enterprise clients - including 63% of Fortune 100 companies. "As we began to launch WeWork Workplace, we saw an incredible opportunity to accelerate the growth and capabilities of our product with the expertise of Yardi's platform. Together, WeWork and Yardi have the ability to build a scalable end-to-end solution for powering the future of work. This partnership underscores the importance of delivering holistic solutions that can cater to every type of real estate strategy," said Scott Morey, President of WeWork Technology and Innovation.

07:10 EDT Zomedica announces PulseVet system named official sponsor of AQHA - Zomedica announced that the PulseVet system has been named the Official Shock Wave Therapy of the American Quarter Horse Association, or AQHA. Zomedica's PulseVet system is a in electro-hydraulic shock wave technology for the treatment of a wide variety of conditions in veterinary patients. The high-energy sound waves stimulate cells and release healing growth factors in the body that reduce inflammation, increase blood flow and accelerate bone and soft tissue development. PulseVet's technology is used in conditions including tendon and ligament healing, bone healing, osteoarthritis, chronic pain and wound healing.

07:09 EDT USPTO allows 9 Meters Biopharma patent NM-136 for serious metabolic conditions - 9 Meters Biopharma announced that the Company has received notice from the United States Patent and Trademark Office USPTO that U.S. Patent Application No. 16/781,304 is allowed. The patent provides protection for the use of NM-136 for the treatment of hyperphagia, serious metabolic conditions such as obesity, and for reducing fatty tissue buildup in body organs. NM-136 is a long-acting, highly specific humanized anti-GIP monoclonal antibody. NM-136 has been shown to prevent glucose-dependent insulinotropic polypeptidefrom binding to its receptor, which in preclinical obesity models has been shown to significantly decrease weight and abdominal fat by reducing nutrient absorption from the intestine as well as nutrient storage without affecting appetite."The allowance of this patent by the USPTO supports our efforts to further strengthen our pipeline, which includes our advanced co-lead products vurolenatide for short bowel syndrome and larazotide for celiac disease, and aligns with our strategy to develop innovative products that make a meaningful impact on the lives of patients suffering from rare or debilitating diseases," said John Temperato, President and Chief Executive Officer of 9 Meters. "We believe NM-136 has considerable potential in the treatment of a number of metabolic disorders, and we look forward to progressing toward an IND filing."

07:08 EDT Google to invest $9.5B in the U.S. in 2022 - Google and Alphabet CEO Sundar Pichai announced plans to invest approximately $9.5B in Google's U.S. offices and data centers in 2022. "Along with these investments, we expect to create at least 12,000 new full-time Google jobs by the end of the year, and thousands more among our local suppliers, partners and communities," Pichai said. The executive stated: "It might seem counterintuitive to step up our investment in physical offices even as we embrace more flexibility in how we work. Yet we believe it's more important than ever to invest in our campuses and that doing so will make for better products, a greater quality of life for our employees, and stronger communities." Reference Link

07:06 EDT Tilt Holdings' Commonwealth Alternative Care announces 'Puff, Puff, Plant' event - TILT Holdings through its subsidiary Commonwealth Alternative Care invites the Taunton, Mass., community out to its 30 Mozzone Boulevard location for an inaugural "Puff, Puff, Plant" event. The pre-420 event is being held on Friday, April 15, from 3-7 pm. The Taunton location offers both medical and adult-use cannabis products. Designed to create community connections, the "Puff, Puff, Plant" event includes: "Ask the Expert" sessions with CAC's talented team, including cultivators and lab techs; A Terpene Bar tended by a CAC specialist to assist and educate on the world of terpenes; A special 4:20 celebration; Participation by brands Wana, Old Pal, Garden Remedies, Fernway and Good Feels; Doing good for our community by giving to Purpose Locker; Support for local chefs with food trucks on-hand; Swag, swag and more swag!

07:04 EDT Agrify announces multimillion international VFU customer agreement with BioCann - Agrify announced it has signed a definitive agreement with BioCann Pharmaceutical Company, a prominent cannabis cultivator located on the island of Madeira, in Funchal, Portugal. Under the terms of the Agreement, Agrify will install 190 VFUs for BioCann's 25,000 sq. ft. cultivation facility along with access to the Agrify Insights cultivation software. BioCann will be purchasing Agrify's cultivation equipment for $4M, and a 5-year SaaS agreement for Agrify Insights for $2.1M. The first set of 10 VFUs will be installed in the next 3 months, with the remaining 180 units scheduled for Q1, 2023. "We are thrilled to begin introducing our advanced cultivation and extraction solutions to the European market through our customer engagement with BioCann," said Raymond Chang, CEO of Agrify. "With many countries moving towards legalization and the European cannabis market being one of the largest in the world, the European Union represents a significant market opportunity for Agrify and we look forward towards additional international expansion."

07:03 EDT Ginkgo Bioworks and FREDsense partner for water quality biosensors - Ginkgo Bioworks and FREDsense Technologies, a water quality platform company leveraging synthetic biology to build field kits for analysis, announced a partnership to build biosensors for water quality monitoring and detection. Through this partnership, Ginkgo seeks to build four distinct microbial strain biosensors, compatible with FREDsense's field-ready hardware for remote water quality monitoring applications. FREDsense builds portable solutions to efficiently assess the chemicals in the water at the source, allowing for rapid modification of water treatment processes in real-time without the need for external lab equipment. The biosensors in development by Ginkgo aim to enable real-time field detection of harmful molecules, and may be used to generate solutions for groundwater and industrial water management systems.

07:02 EDT Zedge acquires GuruShots for $34.8M - Zedge announced it has acquired GuruShots. GuruShots, headquartered in Israel, offers a platform spanning iOS, Android and the web that gamifies photography by providing a fun, educational and structured way for amateur photographers to compete in a wide variety of contests types showcasing their photos while gaining recognition with votes, badges and awards. On a monthly basis, GuruShots users currently cast over 5B votes in more than 300 competitions. GuruShots currently generates revenue from selling packages of extra abilities via in-app purchases. The total addressable market of amateur photographers using their smartphones to take and publicly share artistic photos is estimated at 30M-40M people per month, having the potential to more than double revenue over time while also propelling growth of the userbase. GuruShots, on a stand-alone basis, has a highly attractive growth profile as a mobile game with social elements and a tightly knit community that we expect will accelerate Zedge's revenue growth with associated investment in user acquisition. GuruShots' expertise in game design mechanics used to drive user engagement and grow revenue can be applied across Zedge's portfolio, where appropriate. GuruShots boasts impressive KPIs, including average revenue per monthly active user of more than $3.50, which is materially higher than the 6c Zedge reported during its most recent quarter, and average monthly revenue per paying user in excess of $50, implying an 18% CAGR over the last six years; GuruShots' user base has attractive demographics, with more than 65% of users in well-developed markets and a meaningful base of paying iOS users and converting GuruShots users to sell their photos within Zedge Premium is an opportunity to increase transactions and bolster Zedge's 'NFTs Made Easy' offering. In addition, there will be up to an $8M retention bonus paid to employees over a three-year period, half in cash and half in stock, tied to continued employment with GuruShots during that time.

07:02 EDT iKena Oncology appoints Marango as CFO, Head of Corporate Development - Ikena Oncology (IKNA) announced the appointment of Jotin Marango, M.D., Ph.D., to Chief Financial Officer, CFO, and Head of Corporate Development. The addition of Dr. Marango comes at a "pivotal time as Ikena expands its targeted oncology programs and corporate development efforts," the company said. Dr. Marango joins Ikena from Aptose Biosciences (APTO), where he served as Senior Vice President, Chief Financial Officer and Chief Business Officer.

07:01 EDT Nasdaq grants View Inc. stay of delisting through end of May - View, Inc. announced that Nasdaq has granted View a stay of delisting through the end of May 2022, consistent with View's expected timeline to become current with filings. View reiterates its expectation to complete its financial restatement and release full year 2021 and Q1 2022 results in May. This includes the Company's restated 2019, 2020 and Q1 2021 financial statements, as well as its Q2 2021, Q3 2021, full year 2021 and Q1 2022 financial statements. Completion of filings would allow View to regain compliance with applicable Nasdaq listing requirements. The company will announce an earnings date and dial-in details closer to the date of expected filing.

07:01 EDT PVH Corp. introduces PVH+ Plan multiyear strategic growth plan - PVH Corp. is holding its 2022 Investor Day to introduce the PVH+ Plan, its multi-year, strategic growth plan, provide an overview of the opportunities to fully leverage the strength of its two iconic global brands in all regions, and share how this plan will achieve the company's financial objectives. A key driver of the PVH+ Plan will be the relentless focus on driving efficiencies to become more cost-competitive and reinvest in key strategic growth drivers. PVH is simplifying how its teams work and identifying efficiencies to fuel initiatives with the greatest positive impact and strongest return. The execution of the PVH+ Plan is expected to achieve the following financial objectives: Revenue: High single-digit compounded annual growth from 2021 to approximately $12.5 billion in 2025. The key drivers of revenue growth across brand, region and channel include: Balanced growth from Calvin Klein and TOMMY HILFIGER globally; High single-digit CAGR in Europe and the Americas; mid-teens CAGR in Asia Pacific; 20%+ CAGR in digital channels; Direct-to-consumer brick & mortar outpacing wholesale brick & mortar; Operating margin: Expected to expand to approximately 15% in 2025; Free cash flow: Expected to be over $1.0 billion in 2025.

06:57 EDT JPMorgan announces new $30B share repurchase program - Effective as of May 1, 2022.

06:53 EDT JPMorgan announces new $30B share repurchase program

06:50 EDT JPMorgan reports Q1 ROE 13%, ROTCE 16%

06:47 EDT Comstock Mining acquires industrial battery storage property for $2.1M - Comstock Mining has a definitive agreement to acquire the Haywood quarry and industrial property from Decommissioning Services for a total of $2.1M in cash and stock. The Haywood property represents approximately 190 industrial acres in Lyon County, Nevada, and is part of one of the industrial parks in Lyon County. The Property has power, water and immediate highway access. The company plans to immediately employ a portion of the property for used lithium-ion battery storage, to support the battery metal recycling operations of LINICO Corporation, one of Comstock's renewable energy subsidiaries. Once the pilot crushing and separating system is operating later this year, the company plans on extracting lithium immediately after crushing and conditioning for market leading yields that maximize lithium recovery for reuse in these electrification products.

06:32 EDT Nice's CXOne portfolio adopted by Deutsche Telekom Global Business - Nice announced a partnership with Deutsche Telekom Global Business, Deutsche Telekom's affiliate offering telecommunications and connectivity solutions to businesses of all sizes including the public sector. As part of the collaboration, Deutsche Telekom Global Business is now offering the CXone portfolio of digital and agent-assisted CX solutions in Europe. With Nice CXone, Deutsche Telekom Global Business customers gain access to a cloud native customer experience platform. Deutsche Telekom Global Business is integrating the Nice CXone CCaaS platform and its applications in the communications projects it launches.

06:31 EDT Box unveils Box Canvas virtual whiteboarding and visual collaboration experience - Box on Tuesday unveiled Box Canvas, a virtual whiteboarding and visual collaboration experience that "connects hybrid teams so they can brainstorm, ideate, and create, together from anywhere." Built natively into Box, and available later this year to all users at no additional cost, Box Canvas will deliver a new way for people to collaborate, while leveraging the enterprise-grade security, compliance, and workflow automation capabilities, the company said in a statement. Box Canvas will be introduced at the Box Content Cloud Summit on Thursday, April 14.

06:19 EDT BlackRock reports Q1 long-term net inflows $113.74B - $86B of quarterly total net inflows also reflect seasonal outflows from cash management.

06:17 EDT BlackRock reports Q1 AUM $9.57T, up 6% y/y

06:09 EDT Boqii receives noncompliance notice from NYSE - Boqii announced that it has received a letter dated April 5 from the New York Stock Exchange, notifying the company that its total market capitalization and stockholders' equity are below the NYSE compliance criteria. Pursuant to applicable NYSE continued listing standards, a company would be considered "below criteria" by the NYSE if its total market capitalization is less than $50M over a 30 trading-day period and its stockholders' equity is less than $50M. A review of the current financial condition of the company by the NYSE shows that, as of April 4, the company's 30 trading-day average market capitalization was approximately $48M and its last reported stockholders' equity as of December 31, 2021 was approximately $32.2M. Accordingly, the company is now subject to the procedures as set forth in Sections 801 and 802 of the NYSE Listed Company Manual, and is required to respond within 90 days of the letter with a business plan that demonstrates compliance with the continued listing standard within 18 months of receipt of the letter. The business plan will be reviewed for final disposition by the Listings Operations Committee of the NYSE.

06:06 EDT Hooker Furniture CEO provides production outlook - Hooker Furniture CEO Jeremy Hoff said, "Incoming orders and backlogs continue to be strong in most divisions. We are concerned about ongoing global logistics constraints and economic headwinds affecting the consumer that could impact short-term demand, such as inflation, high gas prices and the war in Ukraine. We expect production capacity of our Asian suppliers to improve significantly, reaching 100% capacity at some point during Q1, although the full financial impact of this improvement in inventory readiness won't be felt until Q2. We remain optimistic that long-term trends will continue to benefit us, such as demand for housing, the renewed and sustainable focus on home interiors and exteriors, and the Millennial generation entering their prime earning and household formation years. We were also very encouraged by the recently concluded Spring High Point market. Attendance was up significantly compared to both the Fall 2021 and June 2021 markets, more in line with pre-pandemic levels. New products were very well received with major placements across all brands, including new placements of Home Meridian's licensed products".

06:03 EDT Novavax granted conditional marketing authorization for Nuvaxovid by Swissmedic - Novavax announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted Novavax conditional marketing authorization for Nuvaxovid COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. The vaccine, also known as NVX-CoV2373, is the first protein-based vaccine to be authorized for use in Switzerland.

05:27 EDT Partner Communications receives notice regarding labor dispute - Partner Communications reported that the Company received notice of a labor dispute in accordance with the Settlement of Labor Disputes Law, 1957, that was announced by the new general employees union - cellular, internet and hi-tech employees union. According to the notice, the main issues disputed relate to the demand to sign a collective employment agreement in order to determine the rights of Partner employees and their employment security following the transaction for the sale of control of the company to Amphissa. In accordance with the notice, company employees that are employed under a collective employment agreement, may take organizational steps as of April 27. The company cannot assess at this stage the impact of the notice or its realization.

05:22 EDT OneConnect identified by SEC under HFCAA - OneConnect announced that the company is aware of the fact that it was identified by the SEC under the Holding Foreign Companies Accountable Act of the United States, or HFCAA, on April 12. Such identification may have resulted from the company's filing of the annual report on Form 20-F for the fiscal year ended December 31, 2021. The company understands the SEC made such identification pursuant to the HFCAA and its implementation rules issued thereunder, and the identification indicates that the SEC determines that the company used an auditor, whose working paper cannot be inspected or investigated completely by the PCAOB, to issue the audit opinion for its financial statements for the fiscal year ended December 31, 2021. In accordance with the HFCAA, a company will be delisted from a U.S. stock exchange if such company has been identified by the SEC for three consecutive years due to PCAOB's inability to inspect the auditor working paper related to such company. The company has been actively exploring possible solutions to best protect the interest of its stakeholders. On February 28, the company submitted a listing application to the Hong Kong Stock Exchange for dual primary listing of its ordinary shares on the Main Board of the HKEX. The company will continue to comply with applicable laws and regulations in both China and the United States.

05:16 EDT Stellantis to consolidate financial services in China - Following the restructuring of financial services in Europe and the United States, Stellantis announced PSA Finance Nederland, or PFN, a fully owned financing subsidiary of BPF and DPCA have entered into an equity transfer agreement with Dongfeng Group, on the basis of which their respective shares in the JV Dongfeng Peugeot Citroen Auto Finance Company, or DPCAFC, will be sold to Dongfeng Group, subject to regulatory approval. The new structure will align with "Dare Forward 2030" supporting the Company's 'asset light business model' and the new brands set up. "As we continue our push to drive profitable growth in China, we need to also reset our financial services offering in the country, as we have done in other major markets," said Stellantis CEO Carlos Tavares. "This move will greatly support our revival plan in the country while also driving a more seamless customer journey." The proposed transaction should be completed during the second half of 2022 once the required authorizations have been obtained from the relevant anti-trust authorities and banking/finance regulators.

05:10 EDT GlaxoSmithKline to acquire Sierra Oncology for $55 per share - GlaxoSmithKline (GSK) and Sierra Oncology (SRRA) announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology for $55 per share of common stock in cash representing an approximate total equity value of $1.9B. Under the terms of the agreement, the acquisition will be effected through a one-step merger in which the shares of Sierra Oncology outstanding will be cancelled and converted into the right to receive $55 per share in cash. Subject to customary conditions, including the approval of the merger by at least a majority of the issued and outstanding shares of Sierra Oncology, and the expiration or earlier termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the transaction is expected to close in Q3 or before. The per share price represents a premium of approximately 39% to Sierra Oncology's closing stock price on April 12 and a premium of approximately 63% to Sierra's volume-weighted average price over the last 30 trading days. Sierra Oncology's board of directors has unanimously recommended that Sierra's stockholders vote in favor of the approval of the merger. Additionally, stockholders of Sierra Oncology holding approximately 28% of Sierra's outstanding shares, have agreed to vote their shares in favor of approval of the merger. GSK will account for the transaction as a business combination and expects it to be accretive to adjusted EPS in 2024, the expected first full year of momelotinib's sales. The value of the gross assets of Sierra Oncology to be acquired is $109M. The net losses of the business were $95M for the 12 months ended December 31, 2021.